在肺动脉高血压中降低了血红蛋白校正的扩散能力,肺功能和形态保持了肺功能和形态
Ayako Igarashi-Sugimoto1, Ichizo Tsujino2, Hideki Shima1
1Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, N15, N7, Kita-ku, Sapporo, 060-8638, Japan.
Respiratory investigation
|May 9, 2025
概括
即使肺功能正常,肺动脉高血压也会降低肺的扩散能力 (DLCO-Hbc) 和转移系数 (KCO-Hbc). 这些减少与疾病严重程度和存活率相关,表明异质血管病变.
科学领域:
- 肺高血压研究 肺高血压研究
- 呼吸系统生理学 呼吸系统生理学
- 心肺医学 心肺医学
背景情况:
- 众所周知,肺动脉高血压 (PAH) 降低了肺部对一氧化碳的扩散能力和转移系数 (DLCO和KCO).
- 单独的PAH对这些参数的影响及其临床意义仍然不完全理解.
- 这项研究旨在澄清PAH对DLCO和KCO的排他性影响以及它们与其他临床指标的关联.
研究的目的:
- 为了确定肺动脉高血压对DLCO和KCO的具体影响.
- 调查这些肺功能参数与PAH严重程度的已确定的临床标志物之间的关系.
- 探索潜在的机制,包括通风-输液不匹配和血管病理.
主要方法:
- 50名肺动脉高血压患者的回顾性分析.
- 纳入标准:正常的肺功能测试和CT扫描中的正常肺膜.
- 用血红蛋白校正的DLCO (DLCO-Hbc) 和KCO (KCO-Hbc) 的计算;与临床参数的相关性;探索性尸检分析.
主要成果:
- 在PAH患者中,中位数%DLCO-Hbc为62%,%KCO-Hbc为70%.
- DLCO-Hbc与功能类相关,步行6分钟的距离,气膜-动脉氧气差异,心脏输出和死亡率.
- 这两个参数与通风-透气不匹配指数相关.
结论:
- 降低DLCO-Hbc和KCO-Hbc (60-70%) 在PAH患者中存在,即使肺功能和形态被保存.
- 这些减少与临床严重程度和生存结果有关.
- 异质性肺血管病变和由此产生的通风-输液不匹配可能有助于这些发现.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
187
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
187
Pulmonary Hypertension: Classification and Pathogenesis
158
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
158
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
Oxygen Transport in the Blood
2.6K
Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...
2.6K


